ArticleBeyoglu eye journal2026
One-Year Visual, Refractive, Tomographic, and Aberrometric Outcomes of Repeat Corneal Collagen Crosslinking in Eyes with Progressive Keratoconus.
Article in Beyoglu eye journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate visual, refractive, tomographic and aberrometic outcomes of repeat corneal collagen crosslinking (CXL) using Dresden protocol in the management of keratoconus progression at 1-year follow-up. Methods: Charts of consecutive progressive keratoconus patients who underwent repeat corneal collagen CXL using Dresden protocol and had at least 1 year follow-up were retrospectively evaluated. Best spectacle-corrected distance visual acuity (CDVA), manifest refraction, slit lamp biomicroscopy, corneal tomography, corneal aberrometry and endothelial cell counts were evaluated before repeat CXL and at postoperative year-1. At postoperative 1-month, corneal demarcation line depth were evaluated using anterior segment optic coherence tomography. Results: Overall, seven eyes of seven patients with the mean age of 23 (ranged 19 to 27) years were included. The interval between the initial and repeat CXL procedures was 60 (ranged 28 to 89) months. At postoperative month-1, a clear demarcation line could be observed in all patient eyes. The mean demarcation line depth was 250 (ranged 220 to 360) µm. At postoperative month-12, mean CDVA, manifest refraction, topographic indices, and aberrometric outcomes remained stable (p>0.05). Maximum keratometry was reduced more than 1D in two (28.6%) eyes, and remained stable in the remaining five (71.4%) eyes. No significant endothelial cell loss or any other sight-threatening complication was encountered in any patient eye. Conclusion: Repeat corneal CXL seems to be safe and effective in halting keratoconus progression at 1-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.